New York State Psychiatric Institute
New York, 10032, United States
NCT Number: NCT07139106
This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.
Trial opening soon.
Get Notified18 year–59 year
All sexes
Interventional
Phase 4
New York, 10032, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single racemic ketamine hydrochloride 0.5 mg/kg infusion
Time frame: 24 hours post-treatment
Beck Scale for Suicidal Ideation clinician-rated version. Minimum score = 0, Maximum score = 38. Higher scores mean a worse outcome.
Contact information is provided by the study sponsor or research team.
New York State Psychiatric Institute
Other
Dynorphin/Kappa Opioid Receptor Signaling Role in Ketamine's Anti-suicidal Ideation Effect
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728253
Depressive Disorder, Depressive Disorder, Major
Shanghai, China
View Trial DetailsNCT07727005
Depressive Disorder, Depressive Disorder, Major
Munich, Bavaria, Germany
View Trial DetailsNCT07712159
Anxiety Disorders, Depressive Disorder
View Trial DetailsNCT07043738
Behavior, Behavioral Symptoms
View Trial Details